No one should die suffering from breathlessness

All physicians should be prepared to manage dyspnea, especially during the coronavirus disease 2019 pandemic. Dyspnea, a subjective experience of uncomfortable breathlessness, can usually be well managed using subcutaneous medications, with a butterfly infusion set being a good access option because it prevents the need for repeated needle injections and can remain in place for days.

Opioids are the mainstay for managing dyspnea at the end of life

It is suggested that physicians start with opioids, which do not impair respiratory status or hasten death when used appropriately with a symptom focus (e.g., hydromorphone 0.5 mg subcutaneously every 4 h, and 0.5 mg subcutaneously every 30 min, as needed). The dosage should be reassessed frequently. Physicians should be prepared to escalate the dose rapidly if necessary. Subcutaneous opioids are twice as powerful as oral opioids (e.g., hydromorphone 1.0 mg taken orally has about the same effect as 0.5 mg administered subcutaneously).

If dyspnea persists, a benzodiazepine may be added

Benzodiazepines can be helpful, particularly if the patient has associated anxiety (e.g., lorazepam 0.5 mg subcutaneously every 2 h, as needed [the dose can be increased if necessary]). For ongoing refractory dyspnea, palliative sedation may be required. A palliative physician should be involved if progressing to this treatment.

Patients often develop bothersome secretions owing to swallowing difficulties

There is usually no role for suctioning, which is often uncomfortable for patients. Anticholinergics are the medication of choice to reduce secretions. Clinicians may choose between scopolamine and glycopyrrolate depending on whether sedation is preferred (e.g., scopolamine 0.4 mg subcutaneously every 4 h as needed [sedating]; glycopyrrolate 0.4 mg subcutaneously every 4 h as needed [not sedating]). Mouth swabs can be helpful for mouth dryness.

Patients’ dyspnea-related agitation can distress their loved ones

Using an antipsychotic is suggested for managing agitation. Methotrimeprazine is favoured because of its sedative properties (e.g., methotrimeprazine 6.25 mg subcutaneously every 6 h as needed [the dose can be increased if needed]). A benzodiazepine is also sometimes added, particularly near the end of life.

References


Competing interests: Michael Slawnych reports receiving a speaker fee as a member of a speaker bureau, Novartis.

This article has been peer reviewed.

Affiliations: Division of Palliative Care and Libin Cardiovascular Institute, University of Calgary, Calgary, Alta.

Correspondence to: Michael Slawnych, michael.slawnych@ahs.ca